NasdaqGM:ADMABiotechs
The Bull Case For ADMA Biologics (ADMA) Could Change Following Its Higher 2025 Revenue Outlook Revision
Earlier in 2025, ADMA Biologics raised its 2025 revenue outlook to US$510 million, up from prior guidance of more than US$500 million, while modestly revising adjusted net income expectations to reflect a higher effective tax rate.
This updated guidance highlights management’s confidence in the performance of BIVIGAM and Nabi-HB and offers investors clearer visibility into the company’s near-term earnings profile.
Next, we’ll explore how this higher 2025 revenue guidance refines ADMA...